Waning immunity to SARS-CoV-2: implications for vaccine booster strategies.
作者信息
Altmann Daniel M, Boyton Rosemary J
机构信息
Department of Immunology and Inflammation, Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, London W12 0NN, UK.
Department of Infectious Disease, Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, London W12 0NN, UK; Lung Division, Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
出版信息
Lancet Respir Med. 2021 Dec;9(12):1356-1358. doi: 10.1016/S2213-2600(21)00458-6. Epub 2021 Oct 21.
Abstract
摘要
相似文献
1
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies.
Lancet Respir Med. 2021 Dec;9(12):1356-1358. doi: 10.1016/S2213-2600(21)00458-6. Epub 2021 Oct 21.
2
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
3
Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose.
Clin Exp Rheumatol. 2023 Jan;41(1):82-87. doi: 10.55563/clinexprheumatol/ti3tvu. Epub 2022 Jun 13.
4
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
Front Immunol. 2022 Jul 22;13:919408. doi: 10.3389/fimmu.2022.919408. eCollection 2022.
5
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022.
6
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7.
7
Waning of humoral immunity depending on the types of COVID-19 vaccine.
Infect Dis (Lond). 2023 Mar;55(3):216-220. doi: 10.1080/23744235.2023.2165707. Epub 2023 Jan 10.
8
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
9
Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19.
Math Biosci. 2023 Jun;360:108981. doi: 10.1016/j.mbs.2023.108981. Epub 2023 Feb 16.
10
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
Microbiol Spectr. 2022 Oct 26;10(5):e0225722. doi: 10.1128/spectrum.02257-22. Epub 2022 Sep 7.
引用本文的文献
1
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development.
Viruses. 2025 Apr 14;17(4):566. doi: 10.3390/v17040566.
2
Genomic insights into mRNA COVID-19 vaccines efficacy: Linking genetic polymorphisms to waning immunity.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2399382. doi: 10.1080/21645515.2024.2399382. Epub 2024 Sep 10.
3
Immunogenicity and protection efficacy of a COVID-19 DNA vaccine encoding spike protein with D614G mutation and optimization of large-scale DNA vaccine production.
Sci Rep. 2024 Jun 15;14(1):13865. doi: 10.1038/s41598-024-64690-5.
4
A qualitative study examining young peoples' perceptions and adherence to COVID-19 public health guidelines in Ireland.
BMC Public Health. 2023 Sep 26;23(1):1864. doi: 10.1186/s12889-023-16757-7.
5
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine.
iScience. 2023 Aug 11;26(9):107612. doi: 10.1016/j.isci.2023.107612. eCollection 2023 Sep 15.
6
Sensitivity of endemic behaviour of COVID-19 under a multi-dose vaccination regime, to various biological parameters and control variables.
R Soc Open Sci. 2023 May 10;10(5):221277. doi: 10.1098/rsos.221277. eCollection 2023 May.
7
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Sci Rep. 2023 Mar 21;13(1):4648. doi: 10.1038/s41598-023-31198-3.
8
T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters.
Front Immunol. 2023 Jan 24;14:1111629. doi: 10.3389/fimmu.2023.1111629. eCollection 2023.
9
Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2.
Front Immunol. 2023 Jan 19;14:1066123. doi: 10.3389/fimmu.2023.1066123. eCollection 2023.
10
SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
Nat Commun. 2023 Feb 2;14(1):572. doi: 10.1038/s41467-023-36250-4.
本文引用的文献
1
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Lancet Respir Med. 2021 Dec;9(12):1450-1466. doi: 10.1016/S2213-2600(21)00407-0. Epub 2021 Oct 21.
2
COVID vaccine immunity is waning - how much does that matter?
Nature. 2021 Sep;597(7878):606-607. doi: 10.1038/d41586-021-02532-4.
3
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
4
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Nature. 2021 Nov;599(7883):114-119. doi: 10.1038/s41586-021-03944-y. Epub 2021 Sep 6.
5
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity. 2021 Aug 10;54(8):1853-1868.e7. doi: 10.1016/j.immuni.2021.07.008. Epub 2021 Jul 30.
6
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.
Cell Rep Med. 2021 Jul 20;2(7):100354. doi: 10.1016/j.xcrm.2021.100354. Epub 2021 Jul 3.
7
Immunological imprinting of the antibody response in COVID-19 patients.
Nat Commun. 2021 Jun 18;12(1):3781. doi: 10.1038/s41467-021-23977-1.
8
Immunity to SARS-CoV-2 variants of concern.
Science. 2021 Mar 12;371(6534):1103-1104. doi: 10.1126/science.abg7404.
9
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.
Sci Immunol. 2020 Dec 23;5(54). doi: 10.1126/sciimmunol.abf3698.
10
Seasonal coronavirus protective immunity is short-lasting.
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.
Zotero 插件